MétaCan
Menu
Back to cohort
Record W4399727957 · doi:10.1172/jci171136

Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models

2024· article· en· W4399727957 on OpenAlexaff
Jezabel Rodríguez‐Blanco, April Salvador, Robert K. Suter, Marzena Swiderska‐Syn, Isabel Palomo-Caturla, Valentin Kliebe, Pritika H. Shahani, Kendell D. Peterson, María Turos‐Cabal, Megan E. Vieira, Daniel T. Wynn, Ashley J. Howell, Fan Yang, Yuguang Ban, Heather J. McCrea, Frédérique Zindy, Etienne Danis, Rajeev Vibhakar, Anna Jermakowicz, Vanesa Martı́n, Christopher C. Coss, Brent T. Harris, Aguirre De Cubas, X. Steven Chen, Thibaut Barnoud, Martine F. Roussel, Nagi G. Ayad, David J. Robbins

Bibliographic record

VenueJournal of Clinical Investigation · 2024
Typearticle
Languageen
FieldMedicine
TopicNatural Compounds in Disease Treatment
Canadian institutionsChildren’s Health Research Institute
FundersNational Institute of Neurological Disorders and StrokeNational Cancer InstituteVince Lombardi Cancer FoundationHollings Cancer Center, Medical University of South CarolinaNational Institutes of HealthSoutheastern Brain Tumor FoundationAmerican Lebanese Syrian Associated CharitiesFoundation for the National Institutes of HealthAmerican Cancer SocietyAlex's Lemonade Stand Foundation for Childhood CancerV Foundation for Cancer ResearchCollege of Graduate Studies, Medical University of South CarolinaRally FoundationSouthern Regional Education Board
KeywordsTriptolideMedulloblastomaCancer researchIn vivoMedicineDrugPharmacologyToxicityOncologyInternal medicineBiologyApoptosis

Abstract

fetched live from OpenAlex

Most children with medulloblastoma (MB) achieve remission, but some face very aggressive metastatic tumors. Their dismal outcome highlights the critical need to advance therapeutic approaches that benefit such high-risk patients. Minnelide, a clinically relevant analog of the natural product triptolide, has oncostatic activity in both preclinical and early clinical settings. Despite its efficacy and tolerable toxicity, this compound has not been evaluated in MB. Utilizing a bioinformatic data set that integrates cellular drug response data with gene expression, we predicted that Group 3 (G3) MB, which has a poor 5-year survival, would be sensitive to triptolide/Minnelide. We subsequently showed that both triptolide and Minnelide attenuate the viability of G3 MB cells ex vivo. Transcriptomic analyses identified MYC signaling, a pathologically relevant driver of G3 MB, as a downstream target of this class of drugs. We validated this MYC dependency in G3 MB cells and showed that triptolide exerts its efficacy by reducing both MYC transcription and MYC protein stability. Importantly, Minnelide acted on MYC to reduce tumor growth and leptomeningeal spread, which resulted in improved survival of G3 MB animal models. Moreover, Minnelide improved the efficacy of adjuvant chemotherapy, further highlighting its potential for the treatment of MYC-driven G3 MB.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.107
GPT teacher head0.411
Teacher spread0.304 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations20
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical InvestigationSame topicNatural Compounds in Disease TreatmentFrench-language works237,207